The Brown University Psychopharmacology Update
September 1, 2026
A systematic review and meta‐analysis encompassing 26 ran‐domized controlled trials (RCTs) has concluded that both single and repeated infusions of ketamine significantly improve suicidality and depressive symptoms in patients with a major depressive episode. Most of the serious adverse events that were reported in the included trials were determined to be unrelated to study treatment.
International Journal of Medical Science and Clinical Research Studies
August 31, 2026
Kumkum Saxena, C Shalini
Depression is a major mental health disorder influenced by biological, psychological, and social factors. Family conflict, lack of social support, and loss of purpose can increase vulnerability to depression. Yoga Prana Vidya (YPV) is an integrated complementary healthcare system that combines rhythmic breathing, meditation, physical exercises, forgiveness practices, no-touch energy healing,...
Zenodo (CERN European Organization for Nuclear Research)
August 31, 2026
preprint
Evidence for psilocybin use in chronic depression is limited, primarily focusing on treatment-resistant cases. While promising results have been noted in studies, more targeted and extensive research is needed.
International Journal of Innovative Technologies in Social Science
August 31, 2026
Anna Szeszko, Weronika Maria Czernek, Magdalena Cichorzewska et al.
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted...
Medical Science
August 30, 2026
Julia Rogała, Kinga Polityńska, Dominika Ruszel et al.
Treatment-resistant depression occurs in roughly one-third of individuals diagnosed with depression.Ketamine and esketamine have appeared as innovative antidepressant treatments that target the glutamatergic system and deliver promising therapeutic options for patients unresponsive to conventional monoaminergic antidepressants.This review delivers a complete analysis of the mechanisms of...
Bipolar Disorders
August 30, 2026
Chih‐Cheng Lin, Lien‐chung Wei
OBJECTIVES: To contextualize the real-world findings of repeated intravenous ketamine infusions for treatment-resistant bipolar depression (TRBPD) and identify priorities for safer, more durable clinical implementation. METHODS: We provide a focused commentary on Zhou et al. (2023) and integrate selected evidence concerning inflammatory and metabolic correlates, neurocognitive outcomes, and...
European Archives of Psychiatry and Clinical Neuroscience
August 29, 2026
Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.
European Journal of Drug Metabolism and Pharmacokinetics
August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Zenodo (CERN European Organization for Nuclear Research)
August 27, 2026
D. Dilhani Indrachapa
preprint
The rapid development of technical power and globalization in the twenty first century have enabled mankind to enjoy unprecedented material comforts but at the same time have presented him with complex social and psychological problems. Young people are experiencing significant mental health issues, mainly stress and depression, in a very competitive society today. This paper investigates...
European Neuropsychopharmacology
August 27, 2026
correction
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].